Tempus and Predicta Biosciences Announce Collaboration to Expand Life Sciences Access to Ultrasensitive Whole-Genome Sequencing Assay for Hematologic Malignancies and MRD Monitoring
MWN-AI** Summary
Tempus AI, Inc. and Predicta Biosciences have announced a strategic collaboration to enhance access to ultrasensitive whole-genome sequencing (WGS) technology aimed at hematologic malignancies and measurable residual disease (MRD) monitoring. The co-branded assay, GenoPredicta™, combines advances in flow cytometry with WGS to provide a comprehensive genomic profile of blood cancers, allowing for the detection of genetic alterations from as few as 50 tumor cells with unmatched sensitivity. This innovation is particularly beneficial for patients with a low tumor burden, potentially broadening eligibility for testing and improving patient outcomes.
GenoPredicta™ identifies a range of genetic alterations, including single nucleotide variants (SNVs), insertions and deletions (indels), copy number variations (CNVs), and structural variants (SVs), crucial for diagnosis and treatment decisions. It has been validated for use in Multiple Myeloma and other plasma cell disorders, while also being available for research purposes across additional indications. The technology has its roots in the pioneering research of Dr. Irene Ghobrial, co-founder of Predicta, whose work has played a significant role in the early detection of blood cancers.
Brian McKernan, CEO of Predicta Biosciences, emphasized the value of this partnership with Tempus, highlighting the assay's potential for improving early detection and treatment strategies, thus enhancing clinical trial efficacy. Similarly, Tempus Chief Scientific Officer Kate Sasser noted the assay's ability to consolidate several testing technologies into a single workflow, offering a unified solution for life science partners and enabling deeper insights while reducing the need for invasive biopsies. This collaboration marks a significant advancement in precision oncology, allowing for improved patient management and tailored treatment options.
MWN-AI** Analysis
The recent collaboration between Tempus AI, Inc. (NASDAQ: TEM) and Predicta Biosciences is a significant development that could reshape the landscape of precision medicine, particularly in the realm of hematologic malignancies and measurable residual disease (MRD) monitoring. Their joint effort to commercialize the GenoPredicta™ whole-genome sequencing (WGS) assay, which boasts remarkable sensitivity and specificity, presents an opportunity for investors to consider their market positions closely.
The GenoPredicta assay's ability to derive insights from as few as 50 tumor cells enhances its utility, allowing for earlier cancer detection and more informed treatment decisions. This could address a critical gap in testing for cancers with low tumor burdens, creating potential avenues for wider adoption in clinical settings. The technology's validation in Multiple Myeloma and other plasma cell conditions indicates promising clinical applications and offers a robust foundation for expanding into new indications.
Investors should note the strategic advantages this partnership may bring to both companies involved. For Tempus, the integration of advanced diagnostics into their AI-driven platform that supports personalized patient care can provide a competitive edge. Predicta, on the other hand, leverages this collaboration to enhance its market footprint, focusing on optimizing clinical trials and expanding into new markets.
The combination of strong scientific backing and technology integration makes this collaboration a key player in the burgeoning field of precision oncology. However, potential investors need to be cautious of the risks highlighted in the forward-looking statements. Regulatory challenges, intellectual property hurdles, and competitive pressures could impact future growth.
In conclusion, the Tempus and Predicta collaboration not only signals a leap forward in oncology diagnostics but also presents a compelling investment narrative amid the growing demand for personalized medicine solutions. Investors should assess their risk tolerance and market position carefully before engaging with the stocks of either company.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, and Predicta Biosciences, a precision oncology company developing novel diagnostic solutions for deep molecular characterization of hematologic malignancies with a focus on circulating tumor cells, today announced the commercial expansion of a co-branded whole-genome sequencing (WGS) assay, currently known as GenoPredicta™, intended for the comprehensive genomic characterization of hematologic malignancies and measurable residual disease (MRD) monitoring.
GenoPredicta is an ultrasensitive assay that extracts deep genetic insights from peripheral blood or bone marrow. By integrating flow cytometry for precise tumor cell detection and enumeration with WGS, the assay delivers a comprehensive analysis of a cancer genome. It identifies genetic alterations (SNVs/indels, CNVs, SVs)—from as few as 50 tumor cells, corresponding to a sensitivity as low as one in a million cells—to aid in diagnosis, risk classification, and the identification of therapy resistance mechanisms. This sensitivity expands testing eligibility to cases with low tumor burden.
The assay is currently available to Tempus’ Life Sciences partners to support exploratory research and clinical development programs. The assay has been clinically validated in Multiple Myeloma and other plasma cell dyscrasias and is available for research use only across other indications. The technology powering the assay stems from the foundational work of Predicta scientific co-founder Dr. Irene Ghobrial, whose research redefined early detection and intervention in blood cancers.
“By joining forces with Tempus, we are delivering unprecedented sensitivity and clarity to researchers - enabling the potential for earlier detection, smarter treatment decisions, and a deeper understanding of disease biology from a single assay,” said Brian McKernan, CEO of Predicta Biosciences. “This partnership with Tempus will help accelerate market adoption and the utility of our tests in order to optimize clinical trials."
"GenoPredicta offers a novel, unified solution for our life science partners and a comprehensive replacement for traditional, siloed testing,” said Kate Sasser, PhD, Chief Scientific Officer at Tempus. “By consolidating flow cytometry, cytogenetics, and WGS into one ultrasensitive workflow, we can identify high-risk biomarkers and track clonal evolution from as few as 50 tumor cells. Crucially, because the assay delivers 100% concordance between peripheral blood and bone marrow, it can provide these deep insights while sparing patients from biopsies."
About Predicta Biosciences:
Founded by pioneering cancer genomics researchers and clinicians, Predicta is a precision oncology company dedicated to transforming the diagnosis, monitoring, and treatment of cancer through novel omics and liquid biopsy diagnostic solutions. The company's proprietary technologies deliver actionable insights that empower clinicians, researchers, and life science partners to better predict treatment response and advance the development of more effective therapies. For more information, visit www.predictabiosciences.com .
About Tempus
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit www.tempus.com .
Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus’ industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, statements regarding expected outcomes and statements regarding the quality of the GenoPredicta assay and its intended use for the comprehensive genomic characterization of hematologic malignancies. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “going to,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release.
You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus’ business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: the intended use of Tempus’ products and services; Tempus’ financial performance; the ability to attract and retain customers and partners; managing Tempus’ growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus’ intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled “Risk Factors” in Tempus’ Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission (“SEC”) on February 24, 2026, as well as in other filings Tempus may make with the SEC in the future. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260415412276/en/
Tempus
Hanah Heintzelman
hanah.heintzelman@tempus.com
FAQ**
How does Tempus AI Inc. (TEM) plan to leverage the GenoPredicta™ assay to enhance its position in the precision oncology market, particularly in light of rising competition?
What specific benefits do you anticipate for clinicians and researchers who utilize the GenoPredicta™ assay developed by Tempus AI Inc. (TEM) and Predicta Biosciences?
Can you elaborate on how the integration of AI into the GenoPredicta™ assay can potentially improve outcomes in hematologic malignancies for patients using Tempus AI Inc. (TEM) technologies?
What strategies will Tempus AI Inc. (TEM) employ to accelerate market adoption of the GenoPredicta™ assay and ensure its accessibility in both research and clinical settings?
**MWN-AI FAQ is based on asking OpenAI questions about Tempus AI Inc. (NASDAQ: TEM).
NASDAQ: TEM
TEM Trading
-0.22% G/L:
$54.36 Last:
1,653,440 Volume:
$57.965 Open:
